Clinical Study

A Phase III Randomized, Double-Blind Study To Evaluate Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Patients With Relapsing Multiple Sclerosis

Posted Date: Oct 23, 2020

  • Investigator: Aram Zabeti
  • Specialties: Multiple Sclerosis, Neurology
  • Type of Study: Drug

The purpose of this research study is to compare the effects, good or bad, of fenebrutinib versus teriflunomide on patients with RMS. Fenebrutinib is an experimental drug that has not yet been approved for treatment of RMS, however, Teriflunomide is approved for the treatment of relapsing forms of MS.

Criteria:

Participant Must Be Between 18-55 That Has Been Diagnosed With Rms With Either Two Documented Clinical Relapses Within The Last 2 Years Or One Documented Clinical Relapse Within 12 Months Of Screening Or Documented Evidence Of The Presence Of A Legion On Mri In The Last 12 Months.

Keywords:

Relapsing Multiple Sclerosis, Neurology, Ms

For More Information:

Tiffany Rupert
513-558-0269
tiffany.rupert@uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.